Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.61 |
| ▸ | POLM | Q9NP87 | 1/20 | 0.45 |
| ▸ | POLK | Q9UBT6 | 1/20 | 0.45 |
| ▸ | POLL | Q9UGP5 | 1/20 | 0.45 |
| ▸ | POLH | Q9Y253 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TOP2A | P11388 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3395761 | 0.99 | ELANE (0.59) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL941862 | 0.84 | ELANE (0.68) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL3207971 | 0.84 | ELANE (0.68) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL126653 | 0.84 | ELANE (0.68) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL3026330 | 0.82 | KMT2A (0.43) | ELANEALOX15KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL13671134 | 0.82 | ELANE (0.87) | ELANE | |
| SCHEMBL125979 | 0.82 | ELANE (0.87) | ELANE | |
| SCHEMBL10943835 | 0.76 | ELANE (0.50) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL10950684 | 0.76 | ELANE (0.50) | ELANEPOLMPOLKPOLLPOLH | |
| SCHEMBL6901164 | 0.74 | LMNA (0.40) | ELANENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183398-B2 | 5-hydroxy-2-methyl-4H-pyran-4-one esters as novel tyrosinase inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2245024-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | Eastman Chemical Company (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | EASTMAN CHEMICAL COMPANY (US) | 2010-08-26 | — | — | US | disclosed |
| WO-2009108272-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE-ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | EASTMAN CHEMICAL COMPANY (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215887-A1 | 5-HYDROXY-2-METHYL-4H-PYRAN-4-ONE ESTERS AS NOVEL TYROSINASE INHIBITORS | TYR, CYP51A1, TH | ELANE 1627/4885POLM 1637/4885POLK 743/4885 |
| US-20100216873-A1 | 5-Hydroxy-2-Methyl-4H-Pyran-4-One Esters as Novel Tyrosinase Inhibitors | TYR, CYP51A1, TH | ELANE 1627/4885POLM 1637/4885POLK 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.